SCHEMBL3073224

SCHEMBL3073224

Cc1nc(-c2ccc(OCCCCl)cc2)oc1C(=O)NCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.50
MAPT P10636 7/20 0.47
LMNA P02545 4/20 0.47
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
TSHR P16473 1/20 0.47
TP53 P04637 3/20 0.46
KDM4E B2RXH2 1/20 0.46
PPARG P37231 2/20 0.45
RXFP1 Q9HBX9 1/20 0.44
GSK3B P49841 1/20 0.44
PPARA Q07869 1/20 0.43
THRB P10828 1/20 0.43
ESR1 P03372 1/20 0.43
MAPK10 P53779 1/20 0.43
KMT2A Q03164 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11624695 0.86 GSK3B (0.55) GAAMAPTLMNASMN1; SMN2TP53
SCHEMBL3080950 0.83 ALDH1A1 (0.50) GAALMNAALDH1A1SMN1; SMN2TP53
SCHEMBL3072528 0.82 HRH3 (0.52)
SCHEMBL3078511 0.80 ALDH1A1 (0.67) GAAMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL3073723 0.78 PPARA (0.48) GAAMAPTLMNAALDH1A1KDM4E
SCHEMBL3082341 0.78 PPARA (0.48) GAAMAPTLMNAALDH1A1TSHR
SCHEMBL3080266 0.75 PPARG (0.45) MAPTLMNAALDH1A1SMN1; SMN2TSHR
SCHEMBL3068151 0.73 HPGD (0.48) LMNAALDH1A1SMN1; SMN2KDM4EPPARG
SCHEMBL3071083 0.72 HRH3 (0.49) GAALMNAALDH1A1SMN1; SMN2TP53
SCHEMBL6580510 0.72 PPARA (0.67) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US claimed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP claimed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 WO claimed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses OXER1, OXTR, OGFR GAA 3115/4885MAPT 4002/4885LMNA 2654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.